The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Keytruda.
Full interview: Scancell back in the clinic with a phase II trial of its flagship skin cancer treatment
Quick facts: Scancell Holdings PLC
Market Cap: £33.74 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE